Defence Therapeutics Stock Current Valuation
| DTCFF Stock | USD 1.00 0.07 7.53% |
Valuation analysis of Defence Therapeutics helps investors to measure Defence Therapeutics' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Defence Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Defence Therapeutics is based on 3 months time horizon. Increasing Defence Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Defence otc stock is determined by what a typical buyer is willing to pay for full or partial control of Defence Therapeutics. Since Defence Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Defence OTC Stock. However, Defence Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0 | Real 0.86 | Hype 1.0 | Naive 1.1 |
The real value of Defence OTC Stock, also known as its intrinsic value, is the underlying worth of Defence Therapeutics OTC Stock, which is reflected in its stock price. It is based on Defence Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Defence Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Defence Therapeutics helps investors to forecast how Defence otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Defence Therapeutics more accurately as focusing exclusively on Defence Therapeutics' fundamentals will not take into account other important factors: Defence Therapeutics OTC Stock Current Valuation Analysis
Defence Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Defence Therapeutics Current Valuation | 60.32 M |
Most of Defence Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Defence Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Defence Therapeutics has a Current Valuation of 60.32 M. This is 99.58% lower than that of the Healthcare sector and 98.7% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 99.64% higher than that of the company.
Defence Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Defence Therapeutics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Defence Therapeutics could also be used in its relative valuation, which is a method of valuing Defence Therapeutics by comparing valuation metrics of similar companies.Defence Therapeutics is currently under evaluation in current valuation category among its peers.
Defence Fundamentals
| Return On Equity | -4.15 | |||
| Return On Asset | -1.79 | |||
| Current Valuation | 60.32 M | |||
| Shares Outstanding | 37.85 M | |||
| Shares Owned By Insiders | 5.26 % | |||
| Price To Book | 36.71 X | |||
| EBITDA | (7.32 M) | |||
| Net Income | (7.34 M) | |||
| Cash And Equivalents | 506.7 K | |||
| Cash Per Share | 0.01 X | |||
| Current Ratio | 0.61 X | |||
| Book Value Per Share | (0.03) X | |||
| Cash Flow From Operations | (6.04 M) | |||
| Earnings Per Share | (0.15) X | |||
| Market Capitalization | 143.45 M | |||
| Total Asset | 719.67 K | |||
| Z Score | -33.0 | |||
| Net Asset | 719.67 K |
About Defence Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Defence Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Defence Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Defence Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Defence OTC Stock
Defence Therapeutics financial ratios help investors to determine whether Defence OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Defence with respect to the benefits of owning Defence Therapeutics security.